<DOC>
	<DOCNO>NCT00382356</DOCNO>
	<brief_summary>The study determine safety efficacy Dutasteride patient fail Finasteride therapy symptomatic benign prostatic enlargement/ hypertrophy ( BPE/H ) .</brief_summary>
	<brief_title>Dutasteride After Failure Finasteride In Management Symptomatic Prostatic Enlargement/Hypertrophy ( BPE/H )</brief_title>
	<detailed_description>STUDY SUMMARY TITLE : A Pilot Investigation Dutasteride ( Avodart ) After Failure Finasteride ( Proscar ) Management Symptomatic Prostatic Enlargement/Hypertrophy OBJECTIVE : To determine safety efficacy Dutasteride patient fail Finasteride therapy symptomatic benign prostatic enlargement/ hypertrophy ( BPE/H ) EXPERIMENTAL PLAN : PATIENT SELECTION : Inclusion Criteria 1 . Patients demonstrate clinical evidence failure treatment Finasteride 12 month . Failure include one following : ( ) AUA SS &gt; 10 ; ( ii ) Q-max &lt; 10 cc/sec ; ( iii ) Post void residual volume ( PVR ) &gt; 200cc . 2 . Patients remain subjectively symptomatic LUTS secondary BPH treatment Finasteride least six month . Exclusion Criteria Patients Neurogenic Bladder/LUTS secondary neurologic disease Patients diagnosis prostate cancer Patients allergy Finasteride/Dutasteride STUDY DESIGN AND DURATION : This single institution , open label pilot study involve 26 patient 18-24 month . Each patient treat standard dose Dutasteride least twelve month follow additional 12 month . EFFICACY AND SAFETY MEASUREMENTS : Improvement flowmetry , AUASS PVR primary outcome measure efficacy . Quality life measurement make also . The exploratory measure include PSA prostate volume . All adverse event include tolerability test agent record . SUMMARY : A positive result show objective ( AUASS , Q-max , PVR ) subjective ( satisfaction index ) improvement previously treat patient engender interest multicenter study confirm data . The clinical import population switch Dutasteride without prolonged treatment Finasteride additional benefit patient . A failure treatment one hormonal agent necessarily imply lack response another agent class .</detailed_description>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<mesh_term>Finasteride</mesh_term>
	<criteria>1 . Male history treatment Finasteride six month , demonstrate clinical evidence failure ( subjective symptom bladder outlet obstruction secondary BPHrelated LUTS ; objective evidence : AUASS &gt; 10 ; Qmax &gt; 5cc/sec &lt; 10c/sec ( total voided volume least 125cc ) ; post void volume &gt; 200cc ) 2 . Prostate volume &gt; 30cc &lt; 80cc transrectal ultrasound measurement 3 . Total Serum PSA &lt; 15 ng/ml ( correct Finasteride therapy ) 4 . Willingness ability give write informed consent comply study instruction procedure . 1 . Clinical evidence nonresponse therapy Finasteride symptomatic BPH . 2 . Total serum correct PSA great 15 ng/ml 3 . History clinical evidence prostate cancer 4 . History acute urinary retention three month prior .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Benign Prostatic Enlargement</keyword>
	<keyword>Benign Prostatic Hypertrophy</keyword>
	<keyword>Dutasteride</keyword>
	<keyword>5-alpha reductase inhibitor</keyword>
	<keyword>Hormonal therapy</keyword>
</DOC>